相似文献
1
Antibody Response to Respiratory Syncytial Virus Vaccination in Immunocompromised Persons.免疫功能低下人群对呼吸道合胞病毒疫苗接种的抗体反应。
JAMA. 2025 Feb 4;333(5):429-432. doi: 10.1001/jama.2024.25395.
2
Respiratory syncytial virus prevention in immunocompromised hosts: gaps and opportunities.免疫功能低下宿主中呼吸道合胞病毒的预防：差距与机遇
Curr Opin Infect Dis. 2025 Aug 1;38(4):300-304. doi: 10.1097/QCO.0000000000001124. Epub 2025 Jun 5.
3
Host immune response to respiratory syncytial virus infection and its contribution to protection and susceptibility in adults: a systematic literature review.成人对呼吸道合胞病毒感染的宿主免疫反应及其对保护作用和易感性的影响：一项系统文献综述
Expert Rev Clin Immunol. 2025 Jun;21(6):745-760. doi: 10.1080/1744666X.2025.2494658. Epub 2025 May 2.
4
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection.免疫球蛋白治疗住院婴儿和幼儿呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD009417. doi: 10.1002/14651858.CD009417.pub3.
5
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease.呼吸道合胞病毒相关下呼吸道疾病的估计疫苗效力
JAMA Netw Open. 2024 Dec 2;7(12):e2450832. doi: 10.1001/jamanetworkopen.2024.50832.
6
Efficacy, safety, and immunogenicity of the AS01-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.AS01佐剂呼吸道合胞病毒预融合F蛋白疫苗（RSVPreF3 OA）在三个呼吸道合胞病毒流行季中对老年人的有效性、安全性和免疫原性（AReSVi-006）：一项多中心、随机、观察者盲法、安慰剂对照的3期试验
Lancet Respir Med. 2025 Jun;13(6):517-529. doi: 10.1016/S2213-2600(25)00048-7. Epub 2025 Apr 14.
7
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.帕利珠单抗用于预防囊性纤维化患儿的呼吸道合胞病毒感染。
Cochrane Database Syst Rev. 2016 Jul 20;7(7):CD007743. doi: 10.1002/14651858.CD007743.pub6.
8
Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth.在母体接种呼吸道合胞病毒疫苗与分娩之间延长间隔时间可提高胎盘抗体转移效率。
Am J Obstet Gynecol. 2024 Nov 7. doi: 10.1016/j.ajog.2024.10.053.
9
Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.加拿大孕妇和产后人群对孕期呼吸道合胞病毒疫苗接种与婴儿单克隆抗体的接受度和偏好。
Vaccine. 2025 Mar 19;50:126818. doi: 10.1016/j.vaccine.2025.126818. Epub 2025 Feb 6.
10
Hydrophobic residue substitutions enhance the stability and immunogenicity of respiratory syncytial virus fusion protein.疏水残基取代增强呼吸道合胞病毒融合蛋白的稳定性和免疫原性。
J Virol. 2025 Jun 17;99(6):e0008725. doi: 10.1128/jvi.00087-25. Epub 2025 May 28.
引用本文的文献
1
RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons.呼吸道合胞病毒疫苗在两个季节对60岁及以上美国成年人住院治疗的有效性
JAMA. 2025 Aug 30. doi: 10.1001/jama.2025.15896.
2
Early risk identification for recurrent wheezing in children with respiratory syncytial virus infections.呼吸道合胞病毒感染儿童复发性喘息的早期风险识别
Am J Transl Res. 2025 Jul 15;17(7):5411-5422. doi: 10.62347/FBSN3075. eCollection 2025.
3
Adult Vaccinations Today-Innovations and Challenges for the Coming Years.当今成人疫苗接种——未来几年的创新与挑战
Vaccines (Basel). 2025 May 29;13(6):583. doi: 10.3390/vaccines13060583.
4
Immunosuppressive Therapy Modifies Anti-Spike IgG Subclasses Distribution After Four Doses of mRNA Vaccination in a Cohort of Kidney Transplant Recipients.免疫抑制疗法改变了一组肾移植受者在四剂 mRNA 疫苗接种后的抗刺突 IgG 亚类分布。
Vaccines (Basel). 2025 Jan 25;13(2):123. doi: 10.3390/vaccines13020123.
本文引用的文献
1
Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.呼吸道合胞病毒（RSV）疫苗对美国 60 岁及以上成年人因 RSV 相关住院和急诊就诊的有效性，2023 年 10 月至 2024 年 3 月：一项阴性检测设计分析。
Lancet. 2024 Oct 19;404(10462):1547-1559. doi: 10.1016/S0140-6736(24)01738-0.
2
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.老年人呼吸道合胞病毒预融合F蛋白疫苗
N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604.
3
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.呼吸道合胞病毒挑战研究中成人的疫苗效力。
N Engl J Med. 2022 Jun 23;386(25):2377-2386. doi: 10.1056/NEJMoa2116154.
4
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.一项评估呼吸道合胞病毒融合前 F 疫苗与流感灭活疫苗在成人中联合应用的免疫原性、安全性和耐受性的 1/2 期随机研究。
J Infect Dis. 2022 Jun 15;225(12):2056-2066. doi: 10.1093/infdis/jiab611.
5
Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes.患有呼吸道合胞病毒感染的成年患者：实体器官及造血干细胞移植对治疗结果的影响。
Transpl Infect Dis. 2015 Aug;17(4):551-7. doi: 10.1111/tid.12409. Epub 2015 Jul 6.
6
Immunological assessment of influenza vaccines and immune correlates of protection.流感疫苗的免疫学评估和保护的免疫相关因素。
Expert Rev Vaccines. 2013 May;12(5):519-36. doi: 10.1586/erv.13.35.
Zotero 插件